Recruitment

Recruitment Status
Completed
Estimated Enrollment
20

Inclusion Criteria

Symptomatology due to aortic stenosis resulting in a New York Heart Association (NYHA) Functional Classification of II or greater
An STS score ≥10; or Logistic EuroScore I ≥ 15; or a determination by one cardiovascular surgeon and one cardiologist that the co-morbidities not captured by the STS or EuroScore expected to increase the operative mortality risk to > 15%.
75 years of age or older
...
Symptomatology due to aortic stenosis resulting in a New York Heart Association (NYHA) Functional Classification of II or greater
An STS score ≥10; or Logistic EuroScore I ≥ 15; or a determination by one cardiovascular surgeon and one cardiologist that the co-morbidities not captured by the STS or EuroScore expected to increase the operative mortality risk to > 15%.
75 years of age or older
Geographically available, willing to comply with follow up and able to provide written informed consent
Aortic valve annular diameter ≥ 21 and ≤23mm measured by MSCT
Echocardiographic or hemodynamic based evidence of calcific (senile) aortic stenosis with one of the following: aortic valve EOA <1.0 cm2 or 0.6 cm2/m2 , mean aortic valve gradient >40 mmHg or peak aortic valve velocity >4 m/sec

Exclusion Criteria

Patient ineligible for or refuses blood transfusions
LVEF < 30%
Moderate to severe mitral stenosis
...
Patient ineligible for or refuses blood transfusions
LVEF < 30%
Moderate to severe mitral stenosis
Life expectancy < 1 year due to non-cardiac co-morbid conditions
Untreated clinically significant coronary artery disease requiring revascularization
Echocardiographic evidence of intracardiac mass, thrombus or vegetation
Severe (Grade 3 to 4) aortic, mitral or tricuspid valve regurgitation
Congenital unicuspid or bicuspid aortic valve, or noncalcified aortic valve; or valve eccentricity (calcific or otherwise) that in the opinion of the investigator could compromise procedural success.
Hypersensitivity or contraindication to procedural medication and device materials (e.g. titanium, nickel, pork) which cannot be adequately pre-medicated
Presence of significant aortic disease such as atheroma, thrombus, or aneurysm which, in the opinion of the investigator, precludes safe implant delivery
Need for emergent surgery or intervention other than the investigational procedure
Severe pulmonary hypertension with pulmonary systolic pressure greater than two-thirds of systemic pressure
Pre-existing prosthetic heart valve in any position, or prosthetic ring
Myocardial infarction within the past 30 days*
Active peptic ulcer or gastrointestinal bleeding within the past 90 days*
Renal insufficiency as demonstrated by a serum creatinine > 2.5 mg/dL or end stage renal disease requiring chronic dialysis
Blood dyscrasias defined as: acute leukopenia, acute anemia, acute thrombocytopenia, history of bleeding diathesis or coagulopathy
Currently participating in any investigational drug or device studies that may confound the results of this study
Active infection requiring ongoing treatment
History of any cognitive or mental health status that would interfere with study participation
Hemodynamic instability requiring inotropic drug therapy within the past 14 days or mechanical support within the past 6 months*
Any therapeutic invasive cardiac procedure performed or planned to perform within 30 days of the index procedure, (or 6 months for drug eluting coronary stent or biventricular pacemaker implantation)*
Unfavorable peripheral vascular anatomy or disease (e.g. severe obstructive calcification, severe tortuosity or small vessels) that would preclude passage of catheters from the femoral arterial access to the aorta as evidenced by peripheral MSCT
Stroke or transient ischemic attack within past 6 months*
Uncontrolled hypertension (i.e. blood pressure at baseline > 140 mmHg systolic; or in the opinion of the investigator cannot be controlled by medical therapy).

Summary

Conditions
  • Aortic Valve Stenosis
  • Severe Aortic Stenosis
Type
Interventional
Design
  • Allocation: N/A
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 75 years and 125 years
Gender
Both males and females

Inclusion Criteria

Symptomatology due to aortic stenosis resulting in a New York Heart Association (NYHA) Functional Classification of II or greater
An STS score ≥10; or Logistic EuroScore I ≥ 15; or a determination by one cardiovascular surgeon and one cardiologist that the co-morbidities not captured by the STS or EuroScore expected to increase the operative mortality risk to > 15%.
75 years of age or older
...
Symptomatology due to aortic stenosis resulting in a New York Heart Association (NYHA) Functional Classification of II or greater
An STS score ≥10; or Logistic EuroScore I ≥ 15; or a determination by one cardiovascular surgeon and one cardiologist that the co-morbidities not captured by the STS or EuroScore expected to increase the operative mortality risk to > 15%.
75 years of age or older
Geographically available, willing to comply with follow up and able to provide written informed consent
Aortic valve annular diameter ≥ 21 and ≤23mm measured by MSCT
Echocardiographic or hemodynamic based evidence of calcific (senile) aortic stenosis with one of the following: aortic valve EOA <1.0 cm2 or 0.6 cm2/m2 , mean aortic valve gradient >40 mmHg or peak aortic valve velocity >4 m/sec

Exclusion Criteria

Patient ineligible for or refuses blood transfusions
LVEF < 30%
Moderate to severe mitral stenosis
...
Patient ineligible for or refuses blood transfusions
LVEF < 30%
Moderate to severe mitral stenosis
Life expectancy < 1 year due to non-cardiac co-morbid conditions
Untreated clinically significant coronary artery disease requiring revascularization
Echocardiographic evidence of intracardiac mass, thrombus or vegetation
Severe (Grade 3 to 4) aortic, mitral or tricuspid valve regurgitation
Congenital unicuspid or bicuspid aortic valve, or noncalcified aortic valve; or valve eccentricity (calcific or otherwise) that in the opinion of the investigator could compromise procedural success.
Hypersensitivity or contraindication to procedural medication and device materials (e.g. titanium, nickel, pork) which cannot be adequately pre-medicated
Presence of significant aortic disease such as atheroma, thrombus, or aneurysm which, in the opinion of the investigator, precludes safe implant delivery
Need for emergent surgery or intervention other than the investigational procedure
Severe pulmonary hypertension with pulmonary systolic pressure greater than two-thirds of systemic pressure
Pre-existing prosthetic heart valve in any position, or prosthetic ring
Myocardial infarction within the past 30 days*
Active peptic ulcer or gastrointestinal bleeding within the past 90 days*
Renal insufficiency as demonstrated by a serum creatinine > 2.5 mg/dL or end stage renal disease requiring chronic dialysis
Blood dyscrasias defined as: acute leukopenia, acute anemia, acute thrombocytopenia, history of bleeding diathesis or coagulopathy
Currently participating in any investigational drug or device studies that may confound the results of this study
Active infection requiring ongoing treatment
History of any cognitive or mental health status that would interfere with study participation
Hemodynamic instability requiring inotropic drug therapy within the past 14 days or mechanical support within the past 6 months*
Any therapeutic invasive cardiac procedure performed or planned to perform within 30 days of the index procedure, (or 6 months for drug eluting coronary stent or biventricular pacemaker implantation)*
Unfavorable peripheral vascular anatomy or disease (e.g. severe obstructive calcification, severe tortuosity or small vessels) that would preclude passage of catheters from the femoral arterial access to the aorta as evidenced by peripheral MSCT
Stroke or transient ischemic attack within past 6 months*
Uncontrolled hypertension (i.e. blood pressure at baseline > 140 mmHg systolic; or in the opinion of the investigator cannot be controlled by medical therapy).

Tracking Information

NCT #
NCT02157142
Collaborators
Not Provided
Investigators
  • Principal Investigator: Axel Linke, MD University of Leipzig - Herzzcntrum
  • Axel Linke, MD University of Leipzig - Herzzcntrum
About Us
Innovation
Privacy
Terms
Copyright
Get Well Soon © Copyright 2024